[{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"b3ec16de-b06c-4b4e-97bd-502739a6230d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02664935","created_at":"2021-01-18T12:59:26.753Z","updated_at":"2025-02-25T14:36:10.262Z","phase":"Phase 2","brief_title":"National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02664935","lead_sponsor":"University of Birmingham","biomarkers":" NKX2-1 • TP63","pipe":"","alterations":" ","tags":["NKX2-1 • TP63"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tagrisso (osimertinib) • Ibrance (palbociclib) • Imfinzi (durvalumab) • docetaxel • Koselugo (selumetinib) • Truqap (capivasertib) • fexagratinib (ABSK091) • ceralasertib (AZD6738) • sitravatinib (MGCD516) • vistusertib (AZD2014)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 423","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-05-13"},{"id":"c92b8794-1c47-49f1-88e3-148924bb13cc","acronym":"BISCAY","url":"https://clinicaltrials.gov/study/NCT02546661","created_at":"2021-01-18T12:19:22.211Z","updated_at":"2024-07-02T16:35:15.193Z","phase":"Phase 1","brief_title":"Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer","source_id_and_acronym":"NCT02546661 - BISCAY","lead_sponsor":"AstraZeneca","biomarkers":" HRD • CDKN2A • RB1 • FGFR • CD8 • CCNE1 • MYCN • IFNG • IL6 • IL2 • IL10 • MYCL","pipe":" | ","alterations":" PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification","tags":["HRD • CDKN2A • RB1 • FGFR • CD8 • CCNE1 • MYCN • IFNG • IL6 • IL2 • IL10 • MYCL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • adavosertib (AZD1775) • fexagratinib (ABSK091) • vistusertib (AZD2014) • danvatirsen (AZD9150)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 10/03/2016","start_date":" 10/03/2016","primary_txt":" Primary completion: 03/18/2020","primary_completion_date":" 03/18/2020","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-03-12"},{"id":"31d6ffe2-4ba8-4867-90e7-d162923e570c","acronym":"Lung-MAP","url":"https://clinicaltrials.gov/study/NCT02154490","created_at":"2021-01-18T06:59:07.141Z","updated_at":"2024-07-02T16:35:46.669Z","phase":"","brief_title":"Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer","source_id_and_acronym":"NCT02154490 - Lung-MAP","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • ALK • EML4 • TP63","pipe":" | ","alterations":" EGFR mutation • ALK fusion • TTF1 negative","tags":["EGFR • ALK • EML4 • TP63"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK fusion • TTF1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • Imfinzi (durvalumab) • docetaxel • Talzenna (talazoparib) • Imjudo (tremelimumab-actl) • fexagratinib (ABSK091) • taselisib (GDC-0032) • rilotumumab (AMG 102)"],"overall_status":"Completed","enrollment":" Enrollment 1864","initiation":"Initiation: 07/08/2014","start_date":" 07/08/2014","primary_txt":" Primary completion: 04/01/2022","primary_completion_date":" 04/01/2022","study_txt":" Completion: 04/15/2022","study_completion_date":" 04/15/2022","last_update_posted":"2023-06-01"},{"id":"abcb612f-f636-45d0-ace3-fa22863b4f9b","acronym":"RADICAL","url":"https://clinicaltrials.gov/study/NCT01791985","created_at":"2021-01-18T07:55:16.658Z","updated_at":"2025-02-25T15:05:30.440Z","phase":"Phase 2a","brief_title":"AZD4547 \u0026 Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL)","source_id_and_acronym":"NCT01791985 - RADICAL","lead_sponsor":"Imperial College London","biomarkers":" ER","pipe":" | ","alterations":" EGFR positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • fexagratinib (ABSK091) • anastrozole"],"overall_status":"Completed","enrollment":" Enrollment 52","initiation":"Initiation: 07/01/2012","start_date":" 07/01/2012","primary_txt":" Primary completion: 11/01/2016","primary_completion_date":" 11/01/2016","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2022-08-22"},{"id":"545f4b46-aa6a-4f4c-9242-8f406a200a71","acronym":"","url":"https://clinicaltrials.gov/study/NCT05086666","created_at":"2021-10-21T13:53:10.418Z","updated_at":"2024-07-02T16:36:22.688Z","phase":"Phase 1b/2","brief_title":"A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547","source_id_and_acronym":"NCT05086666","lead_sponsor":"Abbisko Therapeutics Co, Ltd","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fexagratinib (ABSK091)"],"overall_status":"Recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 06/03/2021","start_date":" 06/03/2021","primary_txt":" Primary completion: 08/14/2023","primary_completion_date":" 08/14/2023","study_txt":" Completion: 05/27/2024","study_completion_date":" 05/27/2024","last_update_posted":"2021-10-21"},{"id":"819807a7-627e-40e5-a967-fc5eec1c4f69","acronym":"TARGET","url":"https://clinicaltrials.gov/study/NCT02824133","created_at":"2021-01-18T13:50:52.751Z","updated_at":"2024-07-02T16:36:59.263Z","phase":"Phase 1/2","brief_title":"Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion\"","source_id_and_acronym":"NCT02824133 - TARGET","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" FGFR • TACC3 • TACC1","pipe":" | ","alterations":" FGFR fusion • FGFR1 fusion • FGFR3 fusion • FGFR1 expression • TACC3 expression • FGFR3 expression • FGFR1-TACC1 fusion","tags":["FGFR • TACC3 • TACC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR fusion • FGFR1 fusion • FGFR3 fusion • FGFR1 expression • TACC3 expression • FGFR3 expression • FGFR1-TACC1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fexagratinib (ABSK091)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 09/01/2017","primary_completion_date":" 09/01/2017","study_txt":" Completion: 10/01/2018","study_completion_date":" 10/01/2018","last_update_posted":"2019-05-29"}]